Adakras 200mg Targeted Therapy for KRAS G12C Mutation in NSCLC
Adakras 200mg is a generic formulation of Adagrasib, a targeted therapy. Adagrasib is an oral, irreversible inhibitor of the KRAS G12C ...
19
Aug